UNRESECTABLE MELANOMA

This study tests whether doctors can safely stop standard anti-PD-1 immunotherapy earlier than usual for people with advanced melanoma that cannot be removed surgically. Using PET/CT scans and tumor biopsies as guides, researchers aim to see if shorter treatment still keeps the c…

This study tests a combination of three drugs (dabrafenib, trametinib, and navitoclax) in people with BRAF-mutant melanoma or other solid tumors that have spread or cannot be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 …

This early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…

This study tests whether combining three drugs—an immunotherapy (nivolumab) with two targeted therapies—can shrink or control advanced melanoma that has spread or can't be removed. It includes people with a specific gene mutation (BRAF V600) whose cancer got worse after prior tre…

This study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be surgically removed. About 245 participants were randomly assigned to receive ipilimumab alone or with GM-CSF. The main goal was …

This early-phase study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes that help cancer grow)—in people with advanced melanoma that cannot be surgically removed. The main goals…

This phase III trial tested two different sequences of drugs in 267 people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib), w…

This study tests whether adding a drug called rigosertib to the immunotherapy pembrolizumab can help shrink or control advanced melanoma that has stopped responding to standard immunotherapy. About 7 adults with melanoma that cannot be surgically removed or has spread will receiv…

This early-stage study tests a combination of drugs (tacrolimus, nivolumab, and ipilimumab) in 12 kidney transplant recipients who have advanced skin cancers that cannot be surgically removed. The goal is to see if this treatment can shrink or control the cancer while keeping the…

This early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…

This study tests an experimental therapy called lifileucel, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced melanoma that has not responded to standard treatments. About 100 adults with unresectable or metastatic melanoma will receive this on…

This study tests whether combining two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda)—can shrink tumors in people with advanced melanoma that has stopped responding to standard anti-PD1/L1 therapy. About 43 adults with stage III or IV melanoma t…

This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…

This study tests a new drug, EVX-01, combined with the standard immunotherapy pembrolizumab in 17 adults with advanced melanoma that cannot be removed by surgery. The goal is to see if the combination shrinks tumors better than pembrolizumab alone. Participants have not received …

This study tests whether taking a break from two targeted cancer drugs (dabrafenib and trametinib) works as well as taking them continuously for people with advanced melanoma that has a specific BRAF mutation. About 280 participants with stage III or IV melanoma that cannot be su…

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This study looks at whether eating a high-fiber diet can change the gut bacteria in people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a period of time. The m…